Lycia Therapeutics, Inc. LYCA
Lycia Therapeutics, Inc. (Nasdaq: LYCA) is an immunology/inflammation drug developer. Its lead program, LCA-0061, is in Phase 1 for Food allergy and other allergic diseases. Its next catalyst on record is LCA-0062: Phase 1 clinical trial initiation and initial data (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: LCA-0062 — Phase 1 clinical trial initiation and initial data (H2 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LCA-0061 | Food allergy and other allergic diseases (elevated IgE) | antibody | Phase 1 |
| LCA-0321 | Graves' disease (thyroid-stimulating hormone receptor autoantibodies) | protein/peptide | Phase 1 |
| LCA-0062 | Food allergy and other allergic diseases (IgE-mediated) | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.